
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE53464D8AF43D1305464D00115FBC4A.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmcneph">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363063/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="BMC Nephrology">
<meta name="citation_title" content="The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial">
<meta name="citation_author" content="Amira Reda Muhammad Galal">
<meta name="citation_author_institution" content="Department of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt">
<meta name="citation_author" content="Nahla Mohamed Teama">
<meta name="citation_author_institution" content="Department of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt">
<meta name="citation_author" content="Karema Abu–Elfotuha">
<meta name="citation_author_institution" content="Department of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt">
<meta name="citation_author" content="Ahmed D Alatawi">
<meta name="citation_author_institution" content="Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia">
<meta name="citation_author" content="Hanan Alshareef">
<meta name="citation_author_institution" content="Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 74191 Saudi Arabia">
<meta name="citation_author" content="Ahmed M E Hamdan">
<meta name="citation_author_institution" content="Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 74191 Saudi Arabia">
<meta name="citation_author_institution" content="Prince Fahad bin Sultan Chair for Biomedical Research (PFSCBR), Tabuk, 74191 Saudi Arabia">
<meta name="citation_author" content="Ahmed Aljabri">
<meta name="citation_author_institution" content="Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia">
<meta name="citation_author" content="Mohannad Alshibani">
<meta name="citation_author_institution" content="Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia">
<meta name="citation_author" content="Zeinab AlKasaby Mahmoud Zalat">
<meta name="citation_author_institution" content="Department of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt">
<meta name="citation_publication_date" content="2025 Aug 18">
<meta name="citation_volume" content="26">
<meta name="citation_firstpage" content="468">
<meta name="citation_doi" content="10.1186/s12882-025-04399-3">
<meta name="citation_pmid" content="40826392">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363063/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363063/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363063/pdf/12882_2025_Article_4399.pdf">
<meta name="description" content="Chronic kidney disease (CKD) is a highly prevalent, irreversible, and progressive disease associated with a high cardiovascular risk. We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) ...">
<meta name="og:title" content="The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Chronic kidney disease (CKD) is a highly prevalent, irreversible, and progressive disease associated with a high cardiovascular risk. We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363063/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12363063">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12882-025-04399-3"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12882_2025_Article_4399.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12363063%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12363063/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12363063/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363063/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmcneph.png" alt="BMC Nephrology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMC Nephrology" title="Link to BMC Nephrology" shape="default" href="https://bmcnephrol.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">BMC Nephrol</button></div>. 2025 Aug 18;26:468. doi: <a href="https://doi.org/10.1186/s12882-025-04399-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12882-025-04399-3</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22BMC%20Nephrol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22BMC%20Nephrol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22BMC%20Nephrol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22BMC%20Nephrol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galal%20ARM%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Amira Reda Muhammad Galal</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Amira Reda Muhammad Galal</span></h3>
<div class="p">
<sup>1</sup>Department of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galal%20ARM%22%5BAuthor%5D" class="usa-link"><span class="name western">Amira Reda Muhammad Galal</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Teama%20NM%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Nahla Mohamed Teama</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Nahla Mohamed Teama</span></h3>
<div class="p">
<sup>2</sup>Department of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Teama%20NM%22%5BAuthor%5D" class="usa-link"><span class="name western">Nahla Mohamed Teama</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abu%E2%80%93Elfotuha%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Karema Abu–Elfotuha</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Karema Abu–Elfotuha</span></h3>
<div class="p">
<sup>1</sup>Department of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abu%E2%80%93Elfotuha%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Karema Abu–Elfotuha</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alatawi%20AD%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Ahmed D Alatawi</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Ahmed D Alatawi</span></h3>
<div class="p">
<sup>3</sup>Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alatawi%20AD%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmed D Alatawi</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alshareef%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Hanan Alshareef</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Hanan Alshareef</span></h3>
<div class="p">
<sup>4</sup>Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 74191 Saudi Arabia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alshareef%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hanan Alshareef</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hamdan%20AME%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Ahmed M E Hamdan</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Ahmed M E Hamdan</span></h3>
<div class="p">
<sup>4</sup>Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 74191 Saudi Arabia </div>
<div class="p">
<sup>5</sup>Prince Fahad bin Sultan Chair for Biomedical Research (PFSCBR), Tabuk, 74191 Saudi Arabia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hamdan%20AME%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmed M E Hamdan</span></a>
</div>
</div>
<sup>4,</sup><sup>5,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aljabri%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Ahmed Aljabri</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Ahmed Aljabri</span></h3>
<div class="p">
<sup>6</sup>Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aljabri%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmed Aljabri</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alshibani%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Mohannad Alshibani</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Mohannad Alshibani</span></h3>
<div class="p">
<sup>6</sup>Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alshibani%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mohannad Alshibani</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zalat%20ZAM%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Zeinab AlKasaby Mahmoud Zalat</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Zeinab AlKasaby Mahmoud Zalat</span></h3>
<div class="p">
<sup>1</sup>Department of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zalat%20ZAM%22%5BAuthor%5D" class="usa-link"><span class="name western">Zeinab AlKasaby Mahmoud Zalat</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Clinical Pharmacy, Faculty of Pharmacy (Girls), Al Azhar University, Cairo, Egypt </div>
<div id="Aff2">
<sup>2</sup>Department of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt </div>
<div id="Aff3">
<sup>3</sup>Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia </div>
<div id="Aff4">
<sup>4</sup>Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, 74191 Saudi Arabia </div>
<div id="Aff5">
<sup>5</sup>Prince Fahad bin Sultan Chair for Biomedical Research (PFSCBR), Tabuk, 74191 Saudi Arabia </div>
<div id="Aff6">
<sup>6</sup>Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jan 31; Accepted 2025 Aug 12; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12363063  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40826392/" class="usa-link">40826392</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background/objectives</h3>
<p id="Par1">Chronic kidney disease (CKD) is a highly prevalent, irreversible, and progressive disease associated with a high cardiovascular risk. We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) and/or folic acid (FA) for CKD patients to the standard care on their health-related quality.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">A randomized, prospective, parallel, and controlled clinical trial of CONSORT 80 patients diagnosed with CKD stages 3–5 were stratified by simple randomization into four groups (20 patient/group) and followed up for 6 months. Control group: received standard usual care therapy only; PTX group: received therapeutic dose of PTX added to standard usual care therapy; FA group: received FA added to standard usual care therapy; and PTX and FA group: received both PTX and FA added to their standard usual care therapy. The primary objective was to compare the renal function biochemical parameters for the intervention groups compared to the control group. Meanwhile, the secondary objective was to compare the incidence of readmission to hospitalization with cardiovascular events, incidence of peripheral vascular diseases and Fatigue Assessment Scale (FAS) for the intervention groups compared to the control group.</p></section><section id="sec3"><h3 class="pmc_sec_title">Clinical trial registration</h3>
<p id="Par3">This study’s research was granted authorization by the Research Ethics Committee (REC), Faculty of Medicine, Ain Shams University, No. (FMASU MS UNIV 15/2022) dated to 15/12/2022, and the Ethical Committee in the Faculty of Pharmacy (Girls), Al-Azhar University, No. (313) dated to 22/12/2022. This study was authorized by <a href="https://clinicaltrials.gov/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT05284656" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05284656</a>) and the first date of registration was 16/02/2022. All patients were assigned to write an informed consent.</p></section><section id="sec4"><h3 class="pmc_sec_title">Results</h3>
<p id="Par4">There was a significant improvement in renal function biochemical parameters and a significant reduction in the FAS for the intervention groups compared to the control group.</p></section><section id="sec5"><h3 class="pmc_sec_title">Conclusions</h3>
<p id="Par5">Our results demonstrated that administration of therapeutic doses of PTX and/or FA in CKD patients delayed the progression of advanced chronic kidney disease and has been used successfully improved their health-related quality of life.</p></section><section id="sec6"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12882-025-04399-3.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Chronic kidney disease, Clinical trials, Folic acid, Pentoxifylline, Renal function parameters, Anemia</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par6">Chronic kidney disease (CKD) is a progressive disease affecting more than 10% of the worldwide population [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Besides, it is accounted for 13.4% of the global deaths in 2023 especially in low-income countries [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. The main risk factors for CKD include the age, hypertension and diabetes [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Moreover, people with CKD do not exhibit any symptoms; until the later stages of the disease. Treatment options include replacement therapy or conservative care. Slowing down the course of renal dysfunction, treating certain consequences including anemia, mineral and bone disorders, cardiovascular diseases (CVD), etc., are goals of conservative treatment for CKD [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. The most common complications of CKD include cardiovascular diseases (CVD) which leads to rehospitalization and death [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>].</p>
<p id="Par7">Fatigue is an excessive subjective overwhelming sense of physical and mental exhaustion which is commonly experienced in CKD patients. It impairs daily functional activities, patient’s quality of life and it is associated with poor therapeutic outcomes through raising the mortality rate and suppressing the recovery rate [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>, <a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Numerous factors related to fatigue such as anemia, hemoglobin (Hb), serum albumin, impaired oxygen delivery, altered cardiovascular response to exertion, metabolic acidosis, and inflammatory cytokines; such as c-reactive protein, and IL-6 [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. The nutrient loss, due to diet restriction and chronic inflammation, is very common in CKD patients. This in turn may stimulate progression into anemia and general fatigue [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>].</p>
<p id="Par8">Pentoxifylline (PTX) is a methylxanthine derivative that functions as a phosphodiesterase (PDE) inhibitor [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. It is commonly used to treat peripheral arterial diseases. PTX improves circulation through altering the erythrocyte deformability and enhances capillary microcirculation [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. Owing to this hemorheological property and the hypotensive effect on the intraglomerular pressure, PTX has gained a great interest as a therapeutic agent in patients with kidney disease especially in diabetic patients [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. In addition, on chronic administration, PTX is an effective anti-inflammation, anti-oxidative stress and ameliorating agent against the histological damage and it has a protective effect on the endothelial function [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. It has been in the clinical use since 1972 and has gain approval by Food and Drug Administration (FDA) in 1984 for managing peripheral blood circulation and improving symptoms of blood flow complications [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>].</p>
<p id="Par9">
Folic acid (FA) is essential for the synthesis, repair and methylation of the DNA [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. FA also participates in single-carbon transfer processes and provides single-carbon units in various oxidative states. Mood disorders, megaloblastic anemia, and hyperhomocysteinemia are among the consequences of folate shortage [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Common unwanted health issues due to folate deficiency include macrocytic anemia, weakness, confusion, memory deficits, shortness of breath, peripheral neuropathy, pregnancy complications and depression [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Hyperhomocysteinemia (Hhcy) occurs in about 85% of CKD patients because of impaired renal metabolism and reduced renal excretion [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. FA, the synthetic form of vitamin B9, is critical in the conversion of homocysteine (Hcy) to methionine. Shortage of FA leads to raising of the Hcy levels [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. Hyperhomocysteinemia (Hhcy) is regarded as an independent predictor of cardiovascular morbidity and mortality in end-stage renal disease [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Hhcy indicates enhanced risks for inflammation, endothelial injury and vascular damage which lead to CVD, stroke, and CKD [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. FA has also been shown to improve endothelial function without lowering Hcy, suggesting an alternative explanation for the effect of FA on endothelial function [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>].</p>
<p id="Par10">
We intended to explore the hypothesis that adding therapeutic doses of PTX (tablets, 400 mg twice daily) and/or FA (tablets, 500 mcg once daily) to the standard usual care has a therapeutic adding effect and has an enhancement effect on the health-related quality of life for CKD stages 3–5 patients.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Study design and oversight</h3>
<p id="Par11">It was a randomized, single-center, prospective, open-label, parallel, and controlled clinical trial conducted at El Demirdash Hospital in Cairo, Egypt, in the nephrology clinics and departments. Randomization were implemented and controlled through central computer. The outcome assessors and the data analysts assigned to the intervention were blinded in order to assure the elimination of any bias.</p>
<section id="Sec4"><h4 class="pmc_sec_title">Clinical trial registration</h4>
<p id="Par12">This study’s research was approved by the relevant Institutional Review Boards. Besides, the study was authorized by <a href="https://clinicaltrials.gov/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT05284656" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05284656</a>) and the first date of registration was 16/02/2022. An informed consent was obtained from the included patients.</p></section><section id="Sec5"><h4 class="pmc_sec_title">Inclusion criteria</h4>
<p id="Par13">Patients between 18 and 60 years old were included if they were diagnosed with stage 3–5 CKD and had a stable condition. Stable patients were defined as: no hospitalizations or cardiac problems in the 90 days preceding screening; consistent function of the kidneys (starting serum creatinine must have not been elevated by 50% in the ninety days preceding screening), no modifications in concurrent drugs during the duration of the investigation, and patients who fully concur to take part in the study.</p></section><section id="Sec6"><h4 class="pmc_sec_title">Exclusion criteria</h4>
<p id="Par14">Pregnant and nursing women, patients with severe comorbid conditions expected to have less life expectancy less than 6 months, current administering PTX as well as FA, restrictions for using of PTX drug: previous history of PTX or theophylline allergy, past history of serious retinal hemorrhage or current cerebral hemorrhage, patients diagnosed with a current infections, inflammatory disorders, or those with HIV infection, patients with chronic liver failure, patients who had been given an immunosuppressive treatment, and patients who did not comply (those who did not take their drugs as prescribed during the research).</p></section><section id="Sec7"><h4 class="pmc_sec_title">Consent for participation and publication</h4>
<p id="Par15">An informed consent was obtained from the included patients. The required data does not include identifying images, other personal or clinical details of participants. All procedures and experiments have been performed in accordance with guidelines and regulations of El Demirdash Hospital in Cairo and World Medical Association Declaration of Helsinki. Assigned participants to the interventions had access to the the random allocation sequence.</p></section></section><section id="Sec8"><h3 class="pmc_sec_title">Allocation and study treatment</h3>
<p id="Par16">
Patients were randomly allocated into four groups; 20 patients for each, the control group who received only the standardized usual care therapy throughout the six months, PTX-group who received pentoxifylline (Trental<sup>®</sup> tablets, 400 mg, twice daily) in addition to the standardized usual care therapy throughout the six months, FA-group who received FA (Folic acid<sup>®</sup> tablets, 500 mcg once daily in addition to the standardized usual care therapy throughout the six months, PTX and FA group who received both PTX (Trental<sup>®</sup> tablets, 400 mg, twice daily) and FA (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) in addition to the standardized usual care therapy (Supplementary material <a href="#MOESM1" class="usa-link">S1</a>) throughout the six months. Throughout the six months of the research, patient adherence (using Direct Observed Therapy; DOT, method) [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>] and compliance (using Self-reporting method) [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. The measured primary and secondary parameters at the beginning of treatment were assigned as baseline measurements. Meanwhile, the measured primary and secondary parameters after six months were assigned as six-months measurements.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Endpoints and outcomes</h3>
<p id="Par17">The primary outcome of this study was to compare the renal function biochemical parameters (serum creatinine, serum ferritin, estimated glomerular filtration rate, hemoglobin, international normalized ratio (INR), red blood cell (RBCs), and serum phosphorus and urinary albumin-to-creatinine ratio) for the intervention groups compared to the control group. Meanwhile, the secondary objective of our study was to compare the incidence of readmission to hospitalization with cardiovascular events, incidence of peripheral vascular diseases and health-related QoL using Fatigue Assessment Scale (FAS) for the intervention groups compared to the control group.</p>
<p id="Par18">The primary composite endpoint of the research was worsening the kidney function of any patient, indicated by sustained reduction of the estimated glomerular filtration rate (eGFR) by more than 50% during treatment or death due to either cardiovascular or kidney diseases. Besides, the secondary endpoint was worsening the eGFR by more than 50% without cardiovascular problems, hospitalization for cardiovascular or kidney diseases, and all causes of mortality such as sepsis.</p></section><section id="Sec10"><h3 class="pmc_sec_title">The fatigue assessment scale (FAS)</h3>
<p id="Par19">FAS is an official 10-item, single-dimensional fatigue scale that measures the fatigue and available online in multiple languages: <a href="https://www.wasog.org/education-research/questionnaires.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.wasog.org/education-research/questionnaires.html</a>. We used the official Arabic form:</p>
<p id="Par20"><a href="https://www.ildcare.nl/wp-content/uploads/2022/02/679743_FAS_ARAB.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ildcare.nl/wp-content/uploads/2022/02/679743_FAS_ARAB.pdf</a>.</p>
<p id="Par21">The FAS has been found to be the most promising measure of fatigue with good reliability and validity [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>].</p>
<p id="Par22">Although the questionnaire is very clear, professionally trained healthcare providers were assigned to help the patient to answer the questionnaire and to evaluate each mentioned problem in the questionnaire.</p>
<p id="Par23">
Each item is rated from 1 (never) to 5 (always), thus resulting in a total scaled score ranging from 10 to 50 points, with 10–21 points indicating no fatigue, 22–34 points indicating fatigue and ≥ 35 points indicating extreme fatigue.</p>
<p id="Par24">All metric scaled scores and age were tested with the determined fatigue scaled score with Pearson`s correlation coefficient at the base line and after 6 months. Values above 0.5 indicated a strong effect.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Data collection</h3>
<p id="Par25">
Patients eligible for participation were asked to provide a written consent form and to complete FAS. Additionally, the basic demographic characters: age, gender, health conditions, current medications and laboratory analysis were recorded. Before the study, patients current standardized usual care medications were evaluated to check if there any risk of drug-drug interactions with study medication.</p>
<p id="Par26">
All patients were assessed at baseline and after six months from the start of the therapy, and they were subjected to the following: demographics and history-taking, adverse effect follow-up, patient compliance follow-up, radiological evaluation, laboratory investigation (biochemical markers) including; serum creatinine, estimated glomerular filtration rate, protein /creatinine ratio, serum ferritin, serum calcium, serum phosphorous, international normalization ratio (INR), urine analysis, complete blood count, c-reactive protein and FAS.</p></section><section id="Sec12"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par27">
The sample size was calculated, using G power program for sample size calculation, setting power at 80%, alpha error at 5%, reviewing results from the number of patients admitted to the hemodialysis unit, a sample size of eighty patients was needed.</p>
<p id="Par28">
GraphPad Prism<sup>®</sup> 5 software was used for the analysis of the data. Qualitative data were presented as frequencies (N) and percentages (%). Quantitative data were presented as mean ± standard deviation (SD). Both the students’ t-test and the ANOVA test were performed to analyze the statistical significance of the studied groups. In all statistical tests, a level of significance of 0.05 was used, below which the results were considered to be statistically significant.</p></section></section><section id="Sec13"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec14"><h3 class="pmc_sec_title">CONSORT flow diagram of the study</h3>
<p id="Par29">
As shown in Fig. <a href="#Fig1" class="usa-link">1</a>, in the frame time between December 2021 to January 2023, 138 patients were assessed for their eligibility using both inclusion and exclusion guidelines; 25 patients were excluded (where fifteen patients having chronic liver disorders, seven patients taking immunosuppressive treatment, and three women being pregnant). A total of 113 individuals were eligible to participate in the study. After obtaining their consents, they were allocated at random to a selection of four groups. After eliminating dead cases and non-compliance patients (all adverse effects and causes of non-compliances; as reported in supplementary material <a href="#MOESM1" class="usa-link">S2</a>, eighty of the 113 patients, 20 in each arm, completed the study research and were included in the final analyses.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363063_12882_2025_4399_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6814/12363063/dfdd55990b72/12882_2025_4399_Fig1_HTML.jpg" loading="lazy" id="d33e524" height="629" width="708" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>CONSORT flow diagram for the experimental design of the clinical trial</p></figcaption></figure><p id="Par31">
There was no significant difference in predisposing factors (hypertension, diabetes mellitus and chronic use of analgesics) and the comorbid conditions (hypertension, diabetes mellitus, heart failure, hyperlipidemia and anemia) in all the allocated groups (As shown in Table <a href="#Tab1" class="usa-link">1</a>). The reported procedure adheres to the CONSORT guidelines (<a href="http://www.consort-statement.org/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.consort-statement.org/</a>) for reporting clinical trials and BMC Series editorial policies (<a href="http://www.biomedcentral.com/submissions/editorial-policies#standards+of+reporting" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.biomedcentral.com/submissions/editorial-policies#standards+of+reporting</a>.</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Basic characteristics of the patients in the studied groups</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Groups\variables</th>
<th align="left" colspan="1" rowspan="1">Studied group<br><em>N</em> = 80</th>
<th align="left" colspan="1" rowspan="1">Control gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">PTX gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">FA gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">PTX + FA gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Age (years) Mean ± SD</td>
<td align="left" colspan="1" rowspan="1">51.96 ± 6.89</td>
<td align="left" colspan="1" rowspan="1">51.6 ± 6.6</td>
<td align="left" colspan="1" rowspan="1">52.20 ± 7.22</td>
<td align="left" colspan="1" rowspan="1">52.25 ± 7.22</td>
<td align="left" colspan="1" rowspan="1">51.80 ± 6.7</td>
<td align="center" colspan="1" rowspan="1">0.9890*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gender</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male N (%)</td>
<td align="left" colspan="1" rowspan="1">28 (35%)</td>
<td align="left" colspan="1" rowspan="1">4 (20%)</td>
<td align="left" colspan="1" rowspan="1">9 (45%)</td>
<td align="left" colspan="1" rowspan="1">7 (35%)</td>
<td align="left" colspan="1" rowspan="1">8 (40%)</td>
<td align="center" colspan="1" rowspan="1">0.9954*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female N (%)</td>
<td align="left" colspan="1" rowspan="1">52 (65%)</td>
<td align="left" colspan="1" rowspan="1">16 (80%)</td>
<td align="left" colspan="1" rowspan="1">11 (55%)</td>
<td align="left" colspan="1" rowspan="1">13 (65%)</td>
<td align="left" colspan="1" rowspan="1">12 (60%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Health conditions</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hypertension N (%)</td>
<td align="left" colspan="1" rowspan="1">64 (80%)</td>
<td align="left" colspan="1" rowspan="1">15 (75%)</td>
<td align="left" colspan="1" rowspan="1">16 (80%)</td>
<td align="left" colspan="1" rowspan="1">16 (80%)</td>
<td align="left" colspan="1" rowspan="1">17 (85%)</td>
<td align="center" colspan="1" rowspan="1">0.8514*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Diabetes mellitus N (%)</td>
<td align="left" colspan="1" rowspan="1">48 (60%)</td>
<td align="left" colspan="1" rowspan="1">14 (70%)</td>
<td align="left" colspan="1" rowspan="1">11 (55%)</td>
<td align="left" colspan="1" rowspan="1">12 (60%)</td>
<td align="left" colspan="1" rowspan="1">11 (55%)</td>
<td align="center" colspan="1" rowspan="1">0.6223*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chronic use of analgesics N (%)</td>
<td align="left" colspan="1" rowspan="1">10 (12.5%)</td>
<td align="left" colspan="1" rowspan="1">3 (15%)</td>
<td align="left" colspan="1" rowspan="1">2 (10%)</td>
<td align="left" colspan="1" rowspan="1">1 (5%)</td>
<td align="left" colspan="1" rowspan="1">4 (20%)</td>
<td align="center" colspan="1" rowspan="1">0.6822*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Anemia N (%)</td>
<td align="left" colspan="1" rowspan="1">76 (95%)</td>
<td align="left" colspan="1" rowspan="1">19 (95%)</td>
<td align="left" colspan="1" rowspan="1">19 (95%)</td>
<td align="left" colspan="1" rowspan="1">20 (100%)</td>
<td align="left" colspan="1" rowspan="1">18 (90%)</td>
<td align="center" colspan="1" rowspan="1">0.9533*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Heart failure N (%)</td>
<td align="left" colspan="1" rowspan="1">14 (17.5%)</td>
<td align="left" colspan="1" rowspan="1">3 (15%)</td>
<td align="left" colspan="1" rowspan="1">4 (20%)</td>
<td align="left" colspan="1" rowspan="1">3 (15%)</td>
<td align="left" colspan="1" rowspan="1">4 (20%)</td>
<td align="center" colspan="1" rowspan="1">0.9333*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hyperlipidemia N (%)</td>
<td align="left" colspan="1" rowspan="1">4 (5%)</td>
<td align="left" colspan="1" rowspan="1">1 (5%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">1 (5%)</td>
<td align="left" colspan="1" rowspan="1">2 (10%)</td>
<td align="center" colspan="1" rowspan="1">0.9231*</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p36">
<p>*One-way ANOVA test</p>
<p>Control group: Patients received their standard usual care therapy only</p>
<p>PTX gp: pentoxifylline group (Trental<sup>®</sup> tablets, 400 mg, twice daily) + their standard usual care therapy</p>
<p>FA gp: folic acid group (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) + their standard usual care therapy</p>
<p>PTX + FA gp: pentoxifylline (Trental<sup>®</sup> tablets, 400 mg, twice daily) + folic acid (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) group + their standard usual care therapy</p>
<p>N: number of patients. SD: Standard Deviation</p>
<p>Significant difference considered at p-value ≤ 0.05 compared to the control group</p>
<p>Besides, there was no significant difference between the abdominal sonography for renal assessment in all in the allocated groups at baseline (As shown in Table <a href="#Tab2" class="usa-link">2</a>)</p>
</div></div></section><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Abdominal sonography for renal assessment in all study patient groups at baseline</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Abdominal sonography</th>
<th align="left" colspan="1" rowspan="1">Control gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">PTX gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">FA gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">PTX + FA gp<br><em>N</em> = 20</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Normal renal morphology N (%)</td>
<td align="left" colspan="1" rowspan="1">2 (10%)</td>
<td align="left" colspan="1" rowspan="1">2 (10%)</td>
<td align="left" colspan="1" rowspan="1">3 (15%)</td>
<td align="left" colspan="1" rowspan="1">2 (10%)</td>
<td align="center" colspan="1" rowspan="1">0.8562*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grade 1 nephropathy N (%)</td>
<td align="left" colspan="1" rowspan="1">7 (35%)</td>
<td align="left" colspan="1" rowspan="1">8 (40%)</td>
<td align="left" colspan="1" rowspan="1">10 (50%)</td>
<td align="left" colspan="1" rowspan="1">8 (40%)</td>
<td align="center" colspan="1" rowspan="1">0.4596*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grade 2 nephropathy N (%)</td>
<td align="left" colspan="1" rowspan="1">6 (30%)</td>
<td align="left" colspan="1" rowspan="1">5 (25%)</td>
<td align="left" colspan="1" rowspan="1">3 (15%)</td>
<td align="left" colspan="1" rowspan="1">8 (40%)</td>
<td align="center" colspan="1" rowspan="1">0.5236*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grade 3 nephropathy N (%)</td>
<td align="left" colspan="1" rowspan="1">5 (25%)</td>
<td align="left" colspan="1" rowspan="1">5 (25%)</td>
<td align="left" colspan="1" rowspan="1">4(20%)</td>
<td align="left" colspan="1" rowspan="1">2 (10%)</td>
<td align="center" colspan="1" rowspan="1">0.3351*</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p46">
<p>*One-way ANOVA test</p>
<p>Control group: Patients received their standard usual care therapy only</p>
<p>PTX gp: pentoxifylline group (Trental<sup>®</sup> tablets, 400 mg, twice daily) + their standard usual care therapy</p>
<p>FA gp: folic acid group (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) + their standard usual care therapy</p>
<p>PTX + FA gp: pentoxifylline (Trental<sup>®</sup> tablets, 400 mg, twice daily) + folic acid (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) group + their standard usual care therapy</p>
<p>N: number of patients</p>
<p>Significant difference considered at p-value ≤ 0.05 compared to the control group</p>
</div></div></section></section><section id="Sec15"><h3 class="pmc_sec_title">Exploring effect of treatment with therapeutic doses of Pentoxifylline (PTX) (Tablet, 400 mg, twice daily) and/or folic acid (FA) (Tablet, 500 Mcg once daily) on the primary outcome biochemical markers (renal functions; serum creatinine, estimated glomerular filtration rate, serum electrolytes; phosphorus, calcium, ferritin, protein urea; urinary albumin-to-creatinine ratio, hematological parameters; platelet count, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, international normalized ratio, pus cells and RBCs) in the studied groups</h3>
<p id="Par34">Comparison between the control group and the three intervention groups at baseline and after six months showed an improvement of renal function and hematological parameters in the three intervention groups compared to the control group, with a synergistic improvement in all the measured parameters in the PTX + FA group (as shown in Table <a href="#Tab3" class="usa-link">3</a>; Fig. <a href="#Fig2" class="usa-link">2</a>). Combined PTX and FA treatment showed the maximum therapeutic activity for the renal function and hematological parameters (Serum creatinine, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio, serum ferritin, hemoglobin and platelets count number).</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Comparison between the control group and the three intervention groups at baseline and after six months</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="3" colspan="1">Biochemical parameters</th>
<th align="left" colspan="9" rowspan="1">Groups</th>
</tr>
<tr>
<th align="left" colspan="2" rowspan="1">Control gp<br><em>N</em> = 20<br>Mean ± SD</th>
<th align="left" colspan="2" rowspan="1">PTX gp<br><em>N</em> = 20<br>Mean ± SD</th>
<th align="left" colspan="2" rowspan="1">FA gp<br><em>N</em> = 20<br>Mean ± SD</th>
<th align="left" colspan="2" rowspan="1">PTX + FA gp<br><em>N</em> = 20<br>Mean ± SD</th>
<th align="left" rowspan="2" colspan="1">
<em>P</em>-value</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Serum creatinine (mg\dl)</td>
<td align="left" colspan="1" rowspan="1">2.872 ± 0.8901</td>
<td align="left" colspan="1" rowspan="1">2.893 ± 0.9370</td>
<td align="left" colspan="1" rowspan="1">3.335 ± 1.149</td>
<td align="left" colspan="1" rowspan="1">2.483 ± 0.7999</td>
<td align="left" colspan="1" rowspan="1">3.118 ± 1.203</td>
<td align="left" colspan="1" rowspan="1">2.433 ± 0.9851</td>
<td align="left" colspan="1" rowspan="1">3.535 ± 0.9109</td>
<td align="left" colspan="1" rowspan="1">2.563 ± 0.7246</td>
<td align="left" colspan="1" rowspan="1">0.2261*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.5536<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0009</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Estimated glomerular filtration rate (mL/min per 1.73 m<sup>2</sup>)</td>
<td align="left" colspan="1" rowspan="1">23.73 ± 11.74</td>
<td align="left" colspan="1" rowspan="1">24.44 ± 13.38</td>
<td align="left" colspan="1" rowspan="1">17.85 ± 8.671</td>
<td align="left" colspan="1" rowspan="1">24.72 ± 8.735</td>
<td align="left" colspan="1" rowspan="1">22.15 ± 11.12</td>
<td align="left" colspan="1" rowspan="1">33.01 ± 15.74</td>
<td align="left" colspan="1" rowspan="1">17.25 ± 7.217</td>
<td align="left" colspan="1" rowspan="1">27.05 ± 10.42</td>
<td align="left" colspan="1" rowspan="1">0.2094<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.2151<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0009</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Serum phosphorus (mg/ dl)</td>
<td align="left" colspan="1" rowspan="1">4.230 ± 0.9487</td>
<td align="left" colspan="1" rowspan="1">3.944 ± 0.4190</td>
<td align="left" colspan="1" rowspan="1">4.405 ± 1.011</td>
<td align="left" colspan="1" rowspan="1">3.950 ± 0.6163</td>
<td align="left" colspan="1" rowspan="1">4.120 ± 1.535</td>
<td align="left" colspan="1" rowspan="1">4.005 ± 1.142</td>
<td align="left" colspan="1" rowspan="1">4.915 ± 1.400</td>
<td align="left" colspan="1" rowspan="1">4.355 ± 0.7926</td>
<td align="left" colspan="1" rowspan="1">0.1993<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.0531<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0031</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.5325</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0066</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Serum calcium (mg/dl)</td>
<td align="left" colspan="1" rowspan="1">8.523 ± 0.4239</td>
<td align="left" colspan="1" rowspan="1">8.555 ± 0.5359</td>
<td align="left" colspan="1" rowspan="1">8.558 ± 0.6580</td>
<td align="left" colspan="1" rowspan="1">8.879 ± 0.4880</td>
<td align="left" colspan="1" rowspan="1">8.120 ± 0.6802</td>
<td align="left" colspan="1" rowspan="1">8.725 ± 0.4703</td>
<td align="left" colspan="1" rowspan="1">8.228 ± 0.6461</td>
<td align="left" colspan="1" rowspan="1">8.895 ± 0.5224</td>
<td align="left" colspan="1" rowspan="1">0.0536<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.6709<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0039</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Serum ferritin (ng /dl)</td>
<td align="left" colspan="1" rowspan="1">235.3 ± 185.1</td>
<td align="left" colspan="1" rowspan="1">222.4 ± 100.2</td>
<td align="left" colspan="1" rowspan="1">334.1 ± 230.2</td>
<td align="left" colspan="1" rowspan="1">375.3 ± 226.0</td>
<td align="left" colspan="1" rowspan="1">200.6 ± 66.18</td>
<td align="left" colspan="1" rowspan="1">249.7 ± 56.73</td>
<td align="left" colspan="1" rowspan="1">245.1 ± 115.7</td>
<td align="left" colspan="1" rowspan="1">311.2 ± 143.1</td>
<td align="left" colspan="1" rowspan="1">0.0687<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.6181<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0040</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Urinary protein-to-creatinine ratio (mg protein/mg creatinine)</td>
<td align="left" colspan="1" rowspan="1">1.366 ± 1.059</td>
<td align="left" colspan="1" rowspan="1">1.361 ± 0.9978</td>
<td align="left" colspan="1" rowspan="1">1.260 ± 0.6995</td>
<td align="left" colspan="1" rowspan="1">1.023 ± 0.5614</td>
<td align="left" colspan="1" rowspan="1">1.375 ± 0.7759</td>
<td align="left" colspan="1" rowspan="1">1.030 ± 0.6782</td>
<td align="left" colspan="1" rowspan="1">1.794 ± 0.5370</td>
<td align="left" colspan="1" rowspan="1">1.499 ± 0.4663</td>
<td align="left" colspan="1" rowspan="1">0.1584<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.8867<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0002</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0085</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Platelets count ×1000/microlitre of blood</td>
<td align="left" colspan="1" rowspan="1">272.0 ± 97.92</td>
<td align="left" colspan="1" rowspan="1">253.6 ± 69.53</td>
<td align="left" colspan="1" rowspan="1">262.6 ± 95.55</td>
<td align="left" colspan="1" rowspan="1">280.7 ± 89.88</td>
<td align="left" colspan="1" rowspan="1">247.3 ± 70.10</td>
<td align="left" colspan="1" rowspan="1">284.5 ± 77.30</td>
<td align="left" colspan="1" rowspan="1">249.1 ± 87.54</td>
<td align="left" colspan="1" rowspan="1">277.0 ± 98.02</td>
<td align="left" colspan="1" rowspan="1">0.7898<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.1329<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">0.0544<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0009</strong>
<sup><strong>***</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0407</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hemoglobin (Hb)</td>
<td align="left" colspan="1" rowspan="1">9.225 ± 1.692</td>
<td align="left" colspan="1" rowspan="1">9.978 ± 1.507</td>
<td align="left" colspan="1" rowspan="1">9.653 ± 1.552</td>
<td align="left" colspan="1" rowspan="1">10.57 ± 1.418</td>
<td align="left" colspan="1" rowspan="1">8.608 ± 1.329</td>
<td align="left" colspan="1" rowspan="1">10.46 ± 1.129</td>
<td align="left" colspan="1" rowspan="1">9.563 ± 1.498</td>
<td align="left" colspan="1" rowspan="1">10.82 ± 1.172</td>
<td align="left" colspan="1" rowspan="1">0.1316<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">
<em>P</em> &lt; 0.0001<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0005</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Mean corpuscular volume (MCV)</p>
<p>(femolitre/cell)</p>
</td>
<td align="left" colspan="1" rowspan="1">80.46 ± 3.750</td>
<td align="left" colspan="1" rowspan="1">84.72 ± 3.899</td>
<td align="left" colspan="1" rowspan="1">84.11 ± 6.526</td>
<td align="left" colspan="1" rowspan="1">84.11 ± 6.526</td>
<td align="left" colspan="1" rowspan="1">82.47 ± 5.278</td>
<td align="left" colspan="1" rowspan="1">87.18 ± 4.961</td>
<td align="left" colspan="1" rowspan="1">80.17 ± 7.518</td>
<td align="left" colspan="1" rowspan="1">81.69 ± 5.808</td>
<td align="left" colspan="1" rowspan="1">0.1304<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">
<em>P</em> &lt; 0.0001<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">0.2244<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p>Mean corpuscular heamoglobin(MCH)</p>
<p>(picogram /cell)</p>
</td>
<td align="left" colspan="1" rowspan="1">25.67 ± 1.831</td>
<td align="left" colspan="1" rowspan="1">28.27 ± 2.246</td>
<td align="left" colspan="1" rowspan="1">26.62 ± 1.412</td>
<td align="left" colspan="1" rowspan="1">26.62 ± 1.412</td>
<td align="left" colspan="1" rowspan="1">25.61 ± 2.943</td>
<td align="left" colspan="1" rowspan="1">28.65 ± 2.224</td>
<td align="left" colspan="1" rowspan="1">26.24 ± 2.195</td>
<td align="left" colspan="1" rowspan="1">27.79 ± 2.657</td>
<td align="left" colspan="1" rowspan="1">0.4035<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">
<em>P</em> &lt; 0.0001<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0419</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">International normalized ratio (INR)</td>
<td align="left" colspan="1" rowspan="1">1.048 ± 0.03358</td>
<td align="left" colspan="1" rowspan="1">1.026 ± 0.05119</td>
<td align="left" colspan="1" rowspan="1">1.136 ± 0.2551</td>
<td align="left" colspan="1" rowspan="1">1.136 ± 0.2551</td>
<td align="left" colspan="1" rowspan="1">1.126 ± 0.1257</td>
<td align="left" colspan="1" rowspan="1">1.037 ± 0.05187</td>
<td align="left" colspan="1" rowspan="1">1.163 ± 0.1602</td>
<td align="left" colspan="1" rowspan="1">1.072 ± 0.1252</td>
<td align="left" colspan="1" rowspan="1">0.1513<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.1487<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">0.0542<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0092</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0007</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pus cells /high power field (HPF)</td>
<td align="left" colspan="1" rowspan="1">3.143 ± 1.345</td>
<td align="left" colspan="1" rowspan="1">4.086 ± 0.9924</td>
<td align="left" colspan="1" rowspan="1">3.000 ± 1.414</td>
<td align="left" colspan="1" rowspan="1">3.000 ± 1.414</td>
<td align="left" colspan="1" rowspan="1">2.429 ± 0.5345</td>
<td align="left" colspan="1" rowspan="1">4.071 ± 1.592</td>
<td align="left" colspan="1" rowspan="1">3.786 ± 1.776</td>
<td align="left" colspan="1" rowspan="1">3.286 ± 2.289</td>
<td align="left" colspan="1" rowspan="1">0.3309<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.0870<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">0.3940<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0196</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">0.4797<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Red blood cell (RBCs)/high power field (HPF)</td>
<td align="left" colspan="1" rowspan="1">3.030 ± 1.479</td>
<td align="left" colspan="1" rowspan="1">2.927 ± 0.5120</td>
<td align="left" colspan="1" rowspan="1">3.200 ± 1.656</td>
<td align="left" colspan="1" rowspan="1">1.653 ± 0.6781</td>
<td align="left" colspan="1" rowspan="1">2.407 ± 1.116</td>
<td align="left" colspan="1" rowspan="1">2.200 ± 0.6492</td>
<td align="left" colspan="1" rowspan="1">4.100 ± 1.929</td>
<td align="left" colspan="1" rowspan="1">4.000 ± 1.690</td>
<td align="left" colspan="1" rowspan="1">0.2524<strong>*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.8170<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0012</strong>
<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">0.5646<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">0.8189<sup><strong>**</strong></sup>
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p60">
<p>*One-way ANOVA test</p>
<p>**Paired t – test</p>
<p>Control group: Patients received their standard usual care therapy only</p>
<p>PTX gp: pentoxifylline group (Trental<sup>®</sup> tablets, 400 mg, twice daily) + their standard usual care therapy</p>
<p>FA gp: folic acid group (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) + their standard usual care therapy</p>
<p>PTX + FA gp: pentoxifylline (Trental<sup>®</sup> tablets, 400 mg, twice daily) + folic acid (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) group + their standard usual care therapy</p>
<p>N: number of patients. SD: Standard Deviation</p>
<p>Significant difference considered at p-value ≤ 0.05 compared to the control group</p>
</div></div></section><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363063_12882_2025_4399_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6814/12363063/22e14647acd7/12882_2025_4399_Fig2_HTML.jpg" loading="lazy" id="d33e1866" height="749" width="798" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Comparison between the control group and the three intervention groups at baseline and after six months regarding change in: <strong>A</strong>: Serum Creatinine, <strong>B</strong>: Estimated glomerular filtration rate, <strong>C</strong>: Serum phosphorus, <strong>D</strong>: Serum calcium, <strong>E</strong>: Serum ferritin, <strong>F</strong>: Urine albumin/creatinine ratio (U/C), <strong>G</strong>: Platelets count, <strong>H</strong>: Hemoglobin (Hb), <strong>I</strong>: Mean corpuscular volume (MCV), <strong>J</strong>: Mean corpuscular hemoglobin (MCH), <strong>K</strong>: International normalized ratio (INR), <strong>L</strong>: Pus cells, <strong>M</strong>: Red blood cell (RBCs). Bars are Mean+/- SD. a; Significant compared to the mean value at the baseline of the same group</p></figcaption></figure></section><section id="Sec16"><h3 class="pmc_sec_title">Exploring the effect of treatment with therapeutic doses of Pentoxifylline (PTX) (Tablet, 400 mg, twice daily) and/or folic acid (FA) (Tablet, 500 Mcg once daily) of CKD patients in the studied groups on the secondary outcome parameter; the incidence of readmission to hospitalization with cardiovascular events and the incidence of peripheral vascular diseases</h3>
<p id="Par37">Cohort following up of patients during the six months of the experiment showed that significant reduction of the incidence of readmission to hospitalization with cardiovascular events and the incidence of peripheral vascular diseases in three intervention groups compared to the control group, with a synergistic improvement in all the measured parameters in the PTX + FA group (as shown in Table <a href="#Tab4" class="usa-link">4</a>).</p>
<section class="tw xbox font-sm" id="Tab4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>Mean of event rates during the following up in the six months (incidence of readmission to hospitalization with cardiovascular events and incidence of peripheral vascular diseases)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="3" colspan="1"></th>
<th align="left" colspan="8" rowspan="1">Groups</th>
</tr>
<tr>
<th align="left" colspan="2" rowspan="1">Control gp<br><em>N</em> = 20<br>Mean ± SD</th>
<th align="left" colspan="2" rowspan="1">PTX gp<br><em>N</em> = 20<br>Mean ± SD</th>
<th align="left" colspan="2" rowspan="1">FA gp<br><em>N</em> = 20<br>Mean ± SD</th>
<th align="left" colspan="2" rowspan="1">PTX + FA gp<br><em>N</em> = 20<br>Mean ± SD</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
<th align="left" colspan="1" rowspan="1">At baseline</th>
<th align="left" colspan="1" rowspan="1">After 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Incidence of readmission to hospitalization with cardiovascular events</td>
<td align="left" colspan="1" rowspan="1">3.672 ± 0.9701</td>
<td align="left" colspan="1" rowspan="1">5.323 ± 0.6730</td>
<td align="left" colspan="1" rowspan="1">3.165 ± 1.224</td>
<td align="left" colspan="1" rowspan="1">2.973 ± 0.6699</td>
<td align="left" colspan="1" rowspan="1">2.998 ± 1.333</td>
<td align="left" colspan="1" rowspan="1">2.983 ± 0.6751</td>
<td align="left" colspan="1" rowspan="1">3.435 ± 0.8109</td>
<td align="left" colspan="1" rowspan="1">1.423 ± 0.6236</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.5536<sup><strong>*</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>*</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0009</strong>
<sup><strong>*</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>*</strong></sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Incidence of peripheral vascular diseases</td>
<td align="left" colspan="1" rowspan="1">21.63 ± 9.64</td>
<td align="left" colspan="1" rowspan="1">22.23 ± 11.38</td>
<td align="left" colspan="1" rowspan="1">26.45 ± 8.671</td>
<td align="left" colspan="1" rowspan="1">14.92 ± 6.785</td>
<td align="left" colspan="1" rowspan="1">25.15 ± 11.12</td>
<td align="left" colspan="1" rowspan="1">19.01 ± 10.74</td>
<td align="left" colspan="1" rowspan="1">19.25 ± 7.217</td>
<td align="left" colspan="1" rowspan="1">7.05 ± 8.12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P-value</td>
<td align="left" colspan="2" rowspan="1">0.2151<sup><strong>*</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0001</strong>
<sup><strong>*</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>0.0009</strong>
<sup><strong>*</strong></sup>
</td>
<td align="left" colspan="2" rowspan="1">
<strong>&lt; 0.0001</strong>
<sup><strong>*</strong></sup>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p73">
<p>*Paired t – test</p>
<p>Control group: Patients received their standard usual care therapy only</p>
<p>PTX gp: pentoxifylline group (Trental<sup>®</sup> tablets, 400 mg, twice daily) + their standard usual care therapy</p>
<p>FA gp: folic acid group (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) + their standard usual care therapy</p>
<p>PTX + FA gp: pentoxifylline (Trental<sup>®</sup> tablets, 400 mg, twice daily) + folic acid (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) group + their standard usual care therapy</p>
<p>N: number of patients. SD: Standard Deviation</p>
<p>Significant difference considered at p-value ≤ 0.05 compared to the control group</p>
</div></div></section></section><section id="Sec17"><h3 class="pmc_sec_title">Explore of the effect of treatment with therapeutic doses of Pentoxifylline (PTX) (Tablet, 400 mg, twice daily) and/or folic acid (FA) (Tablet, 500 Mcg once daily) of CKD patients in the studied groups on the secondary outcome parameter; the fatigue assessment scale (FAS)</h3>
<p id="Par39">The fatigue Assessment Scale (FAS) for all patients at baseline using FAS showed that all CKD patients were suffering from severe fatigue states (mean fatigue scaled scores of 38.70, 38.50, 38.65, and 38.75 for control, PTX, FA, and PTX + FA groups respectively). There was no significant difference between the four groups (p-value &gt; 0.05), (as shown in Table <a href="#Tab5" class="usa-link">5</a>; Fig. <a href="#Fig3" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="Tab5"><h4 class="obj_head">Table 5.</h4>
<div class="caption p"><p>Comparison of fatigue assessment scale (FAS) for all study groups at baseline and after 6 months</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Groups</th>
<th align="left" colspan="1" rowspan="1">Fatigue scaled score<br>Mean ± SD</th>
<th align="left" colspan="1" rowspan="1">Mean difference from baseline and after six months</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Control group at baseline</td>
<td align="left" colspan="1" rowspan="1">38.70 ± 1.780</td>
<td align="left" rowspan="2" colspan="1">2.4</td>
<td align="left" rowspan="2" colspan="1">
<em>P</em> &lt; 0.0001<sup><strong>*</strong></sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Control group after 6 months</td>
<td align="left" colspan="1" rowspan="1">41.10 ± 2.125</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pentoxifylline group (PTX) at baseline</td>
<td align="left" colspan="1" rowspan="1">38.50 ± 1.906</td>
<td align="left" rowspan="2" colspan="1">1.1</td>
<td align="left" rowspan="2" colspan="1">
<em>P</em> &lt; 0.0001<sup><strong>*</strong></sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pentoxifylline group (PTX) after 6 months</td>
<td align="left" colspan="1" rowspan="1">37.40 ± 1.818</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Folic acid group (FA) at baseline</td>
<td align="left" colspan="1" rowspan="1">38.65 ± 1.725</td>
<td align="left" rowspan="2" colspan="1">2.1</td>
<td align="left" rowspan="2" colspan="1">
<em>P</em> &lt; 0.0001<sup><strong>*</strong></sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Folic acid group (FA) after 6 months</td>
<td align="left" colspan="1" rowspan="1">36.55 ± 1.572</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pentoxifylline and Folic acid group (PTX + FA) at baseline</td>
<td align="left" colspan="1" rowspan="1">38.75 ± 1.713</td>
<td align="left" rowspan="2" colspan="1">3.2</td>
<td align="left" rowspan="2" colspan="1">
<em>P</em> &lt; 0.0001<sup><strong>*</strong></sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pentoxifylline and Folic acid group (PTX + FA) after 6 months</td>
<td align="left" colspan="1" rowspan="1">35.55 ± 1.605</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p83">
<p>*One-way ANOVA test</p>
<p>Control group: Patients received their standard usual care therapy only</p>
<p>PTX gp: pentoxifylline group (Trental<sup>®</sup> tablets, 400 mg, twice daily) + their standard usual care therapy</p>
<p>FA gp: folic acid group (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) + their standard usual care therapy</p>
<p>PTX + FA gp: pentoxifylline (Trental<sup>®</sup> tablets, 400 mg, twice daily) + folic acid (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) group + their standard usual care therapy</p>
<p>N: number of patients. SD: Standard Deviation</p>
<p>Significant difference considered at p-value ≤ 0.05 compared to the control group</p>
</div></div></section><figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363063_12882_2025_4399_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6814/12363063/56226c2c8665/12882_2025_4399_Fig3_HTML.jpg" loading="lazy" id="d33e2234" height="477" width="738" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Comparison of fatigue state using Fatigue Assessment Scale (FAS) for all study groups at baseline and after six months. Control group: Patients received their standard therapy only. Intervention group 1: pentoxifylline group (Trental<sup>®</sup> tablets, 400 mg, twice daily). Intervention group 2: folic acid group (Folic acid<sup>®</sup> tablets, 500 mcg, once daily). Intervention group 3: pentoxifylline (Trental<sup>®</sup> tablets, 400 mg, twice daily) + folic acid (Folic acid<sup>®</sup> tablets, 500 mcg, once daily) group. a; Significant compared to the corresponding mean in the control group, b; Significant compared to the baseline in the same group</p></figcaption></figure><p id="Par42">After six months, FAS was repeated for all patients. In the control group, there was a highly significant difference in mean fatigue scaled score (p value &lt; 0.0001) at baseline and after six months from the start of the treatment, as the mean fatigue scaled score increased by 2.4. In the PTX + FA group, there was a highly significant difference in mean fatigue scaled score (p value &lt; 0.0001) at baseline and after six months; decreased by 3.2, followed by the FA group, decreased by 2.1, and followed by PTX group, decreased by 1.1.</p></section></section><section id="Sec18"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par43">Up till now, there is no specific treatment for most of the acquired chronic kidney diseases (CKDs). Renal transplantation is limited by organ shortage that is not likely to be resolved in the immediate or near future. Therefore, the best current therapeutic option is to concentrate on preventing the progression of renal diseases [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>, <a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>].</p>
<p id="Par44">We aimed to investigate and compare the effects of the administration of therapeutic doses of pentoxifylline (PTX) and/or folic acid on patients with chronic kidney disease (CKD) in order to provide nephroprotection options that could delay the progression of advanced chronic kidney disease. Therapeutic doses of pentoxifylline and/or folic acid showed statistically significant decreasing in serum creatinine, serum phosphorus and urinary protein-to-creatinine ratio. Meanwhile, there were statistically significant increases in estimated glomerular filtration rate (eGFR), serum calcium, hemoglobin, and mean corpuscular hemoglobin (MCH) after six months compared to the baseline values. Besides, we found that there were statistically significant decreases for the urinary protein-to-creatinine ratio in the PTX group after six months compared to the baseline, while there were no statistically significant differences in the control group after six months compared to the baseline. This result was in agreement with Chen et al. [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. Yet, that study used 800 mg of PTX once daily. Moreover, our results were also in accordance with the findings of Renke et al. [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. In that study, a placebo-controlled cross-over study was used. They found that PTX at a dose of 1200 mg daily reduced proteinuria [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. We got the same results with lower doses of PTX and less patient non-compliance. Besides, our results shed the light that the nephroprotective effect of pentoxifylline affects by the daily dose. Previous researches [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>, <a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>], used one daily doses of pentoxifylline [800 and 1200 mg respectively once daily] which may have high patient non-compliance. So, we can divide the dose of pentoxifylline in order to get the same nephroprotective effect with decreased the patient non-compliance. Moreover, we designed our clinical trial in order to include diabetic, hypertensive or both diseased patients. All of those previous studies and our studies, concentrate on the treatment of the therapeutic outcomes for using the therapeutic doses of pentoxifylline and folic acid as a therapeutic option for improving the kidney function parameters and resultant reduction of the quality of life; represented by the fatigue. The etiology of the CKD such as nephropathy, hypertensive nephrosclerosis, glomerulonephritis, or other causes, which greatly affects the prognosis of the CKD and the development of fatigue should be investigated in future studies in order to generalize our findings. Focus groups for each comorbid factor should be designed in order to judge the generalizability of those findings.</p>
<p id="Par45">On the other hand, Perkins et al., in a pilot randomized double-blind placebo-controlled trial, found that proteinuria level was significantly different between the PTX and placebo groups after one year compared to the baseline suggesting that it is not before one year till the therapeutic dose of PTX to enhance the eGFR [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. The sample size in that study and the following up procedure might lack the accuracy. In our study, we directly followed up the patients for six months and the sample size was higher than that study. The reduction of the glomerular filtration rate in that research was slower between the six months to the twelve months compared to our study. This may be due to administration of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers which is affected by the electrolyte imbalance and sodium in taking prior to the start of treatment [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>].</p>
<p id="Par46">In our present study, there was a statistically significant increase (<em>P</em> &lt; 0.05) in the PTX group after six months compared to the baseline regarding the eGFR, with no statistically significant difference in the control group. So, the therapeutic dose of PTX significantly enhanced the kidney function.</p>
<p id="Par47">On the other hand, Perkins et al., showed that the mean eGFR decreased in the assigned PTX group and the controlled placebo group. But the mean eGFR decrease was significantly less in the PTX group than the placebo group [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. This may be due to the difference in the experimental design between the two studies.</p>
<p id="Par48">Our results go along with those of the Goicoechea et al. study [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. There was a change in eGFR after twelve months in PTX group patients, whereas in the control group there was a worsening by the end of the study. That study used inflammatory biomarkers for their results. In our study we focused on both the biomarkers and the fatigue; as an output of the health condition, well as. So, our study took into account the fatigue condition of the CKD patients. Moreover, our results were also similar to that reported by Johnson et al. [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. PTX-group showed significantly increased hemoglobin concentration [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. Treatment with under-therapeutic dose of PTX dose had no effect on the hyporesponsiveness of ESAs with enhanced patients’ quality of life. So, our data for the reduction of the fatigue scaled score go along with this study. Additionally, our findings go along with Chen et al., [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. Treatment with therapeutic dose of PTX for six months resulted in significant reduction of the protein excretion level. Besides, our result is similar to those of Nanayakkara et al., a randomized, double-blind trial [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. Participants treated with different anti-oxidants or placebo showed improved eGFR in CKD patients. The similarity of their results and ours is due to the power of PTX to relief the oxidative stress produced during CKD which produces inflammation [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>, <a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. So, it has the same antioxidant effect.</p>
<p id="Par49">In contrast, House et al.‘s multicenter, randomized, double-blind, placebo-controlled trial, showed that eGFR decreased in the B-vitamin group after 36 months of continuous treatment. So high doses of B vitamins and longtime treatment resulted in a greater decrease in GFR and an increase in vascular events [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. In that study, authors excluded CKD patients with stage 4 and 5. So, this may explain the difference between our results and that results and the need for high doses of vitamin B for long time of treatment.</p>
<p id="Par50">Yang et al. evaluated and compared the efficacy of folic acid and pentoxifylline on renal protection in predialysis patients with advanced CKD [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Even though, that previous study had just investigated and compared the effects of folic acid and pentoxifylline on delaying dialysis initiation in predialysis patients with advanced CKD and devoid many laboratory data (such as creatinine and eGFR), To the best of our knowledge, we are the first study to compare the efficacy of folic acid and/or pentoxifylline on renal protection based on laboratory data such as serum creatinine, urinary protein-to-creatinine ratio, estimated glomerular filtration rate, serum calcium, hemoglobin, and serum ferritin. Moreover, Yang et al.‘s study was a retrospective population-based observational study. Our study is a well-designed prospective study with measured all biochemical parameters with the fatigue scaled score for patients.</p>
<p id="Par51">It has been reported that PTX has anti-inflammatory, anti-proinflammatory cytokines and anti-hypoxia-inducible factor-2alpha (HIF-2alpha) leads to improvement of the glomerular filtration rate (eGFR) and significantly having anti-proteinuric effect. These explanations have been previously explained the improvement of the renal function parameters in chronic kidney disease (CKD) patients (Stages 3–5) over at least 6 months of clinical trials [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>–<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. Meanwhile, our results showed an unexpected high improvement of the observed renal function (27% improvement). The explanation of this unexpected nature of observed renal improvement includes that most of the hired patients for these clinical trials (80%) are diabetic patients. Pentoxifylline has been proved to show significant antiproteinuric effects in diabetic kidney disease patients [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>], significantly increased serum markers for diabetic kidney health such as Klotho [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], significantly reduced harmful serum tumor necrosis factor-α (TNF-α) in diabetic patients [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>] and a delay in the loss of estimated glomerular filtration rate [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>] in diabetic patients. So, our results for the PTX are more promising for diabetic patients. Meanwhile, further investigations should be done before the addition of PTX to the usual care therapy protocol through investigating the effect of PTX on CKD patients with low inflammatory markers. Besides, no evidence for the primary kidney protective effect of PTX. The biological plausibility of these findings is that PTX inhibits phosphodiesterase isoenzyme (PDE) increases the accumulation of cAMP inside nephrocytes increased the (HIF-2alpha) stimulating the hemoglobin and inhibiting renal fibrosis [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. Besides, PTX decreases the blood viscosity and improves the tissue oxygenation of the kidney. So, it leads to improvement of the kidney condition. These subcellular and hemodynamic explanations have been added to the discussion section and highlighted with yellow. Moreover, we firstly reported that variability in laboratory measurements in the platelets counts and International normalized ratio (INR) are not significantly affected by either PTX or Folic acid (FA) suggesting that alternative mechanisms may be responsible for the agent’s ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anemia [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. The source of novelty in our research is the assessment of the Fatigue Assessment Scale (FAS) as an output for the anemia and the clinical trial for the effect of Foilc acid or combined therapy.</p>
<p id="Par52">Fatigue can be defined as an overwhelming sense of tiredness, lack of energy, and a feeling of exhaustion [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. Fatigue assessment tools include unidimensional fatigue scales such as: Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), Brief Fatigue Inventory, Fatigue Severity Scale, Fatigue Assessment Scale, Numerical Rating Scale – Fatigue, and Visual Analog Scale – Fatigue. The multidimensional fatigue scales found were the Checklist Individual Strength, Chalder Fatigue Scale, Multidimensional Assessment of Fatigue, Multidimensional Fatigue Inventory Scale, and Piper Fatigue Scale [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>, <a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. It has been reported that our used assessment tool; Fatigue Assessment Scale (FAS) tool is the tool of choice for assessing fatigue in CKD [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. In our results, FAS scaled scores for CKD patients exceeds 22 indicating that CKD patients have moderate-to-sever fatigue correlating to the worsening of the quality of health-related life (QoL) and poor clinical outcomes. It is simple validated tool for assessment of the fatigue severity in CKD patients [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>].</p>
<p id="Par53">Previous studies solely focused on biomarkers (such as hemoglobin (Hb) and C-reactive protein (CRP) and neglected investigating the effect of standard medicines on the clinical outcomes or patient quality of life. Johnson et al. showed that treatment with oral dose of 400 mg daily of pentoxifylline for 3 months significantly increased Hb and significantly declined inflammatory cytokines and CRP [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Besides, Cooper et al. investigated end-stage renal disease patients administered 400 mg of pentoxifylline orally per day for 4 months and found a substantial increase in Hb and a significant decrease in TNF-α and IFN-ϒ [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. These results go a long with our results.</p>
<p id="Par54">In our study, we focused on the therapeutic effect of pentoxifylline and folic acid on clinical outcomes by assessing the fatigue scaled score along with all biochemical parameters.</p>
<p id="Par55">To the best of our knowledge, we are the first to investigate the therapeutic effect of pentoxifylline and folic acid in CKD patients (stages 3–5) on clinical outcomes by assessing the fatigue scaled score using the Fatigue Assessment Scale (FAS).</p>
<p id="Par56">In this study, there was a significant decrease in the fatigue scaled score in all the intervention groups before and after the intervention, which was due to the effect of pentoxifylline and folic acid for six months compared to the control group.</p>
<p id="Par57">Contrary to our study, in Fukuda et al. study, authors studied fatigue and quality of life in end-stage renal disease. In this study, patients undergone double blind study of receiving nutrients (mixture of vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folic acid, vitamin C, carnitine, coenzyme Q10, nave galacto-oligosaccharide, and zinc) or placebo after each dialysis session for 12 weeks. They found no significant difference between nutrient-treated patients and placebo-treated patients [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. This can be explained that it measured the biochemical biomarkers and questionnaire for acute and chronic fatigue within twelve weeks of the study. The antioxidant and anti-inflammatory properties of both pentoxifylline and folic acid needs about four months till generation of the whole human blood and the feeling of fatigue can be reduced [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. So, our experimental design is more logic to measure the Fatigue Assessment Scale (FAS) after six months of treatment.</p></section><section id="Sec19"><h2 class="pmc_sec_title">Strengths and limitations of the study</h2>
<section id="Sec20"><h3 class="pmc_sec_title">Strengths of the study</h3>
<p id="Par58">In our study, we used randomized controlled clinical trial, we used two interventions with doses chosen on the basis of prior studies and we evaluated both biomarkers and health-related outcomes for evaluating the therapeutic beneficiaries. This experimental design is appropriate and relevant to the question of our research. Moreover, the inclusion of a patient-reported outcome (FAS) is the first time to be reported as a biomarker for the quality of life for patients with CKD. Besides, the study explores low-cost, potentially accessible treatments for CKD patients in resource-limited Meanwhile, it has been calculated by the center settings.</p>
<p id="Par59">In the current study, there was no significant difference between the control group and intervention groups regarding age, gender, or biochemical parameters at baseline. This indicates good randomization of the cases with the exclusion of any selection bias that could affect the outcome results.</p></section></section><section id="Sec21"><h2 class="pmc_sec_title">Limitations of the study</h2>
<p id="Par60">The present work was limited by the small number of patients due to the difficulty of recruiting patients who met the study criteria. Although. the sample size met the least amount of the sample size calculated by the G-power program, meanwhile, the sample size is relatively small to generalize these findings. Besides, the duration of treatment (six months) should be increased for following up, in order to explore the effect of chronic administration of these medications on the biomarkers and the quality of life of these patients. In addition to, the CKD is significantly influenced by the etiology which is significantly influence the progression and the response to treatment such as diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis, etc. This represents a significant limitation for our study. On the same way, it was a single-center trial.</p></section><section id="Sec22"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par61">In spite of the study limitations including the relatively short study duration (6 months), we can generally conclude that co-administration of therapeutic daily doses of pentoxifylline acid (PTX) and/or folic acid (FA) to chronic kidney disease (CKD) patients with different etiologies has the therapeutic advantage of the ability to delay the progression of CKD by enhancing renal function, improving the biochemical parameters and relieving fatigue which is reflecting positively on their quality of life.</p></section><section id="Sec23"><h2 class="pmc_sec_title">Supplementary Information</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12363063/bin/12882_2025_4399_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (19.1KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12363063/bin/12882_2025_4399_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (32.4KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Not applicable.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Conceptualization, Amira Galal, Nahla Teama and Zeinab Zalat; Data curation, Nahla Teama, Karema Abu –Elfotuha, Ahmed Alatawi, Hanan Alshareef, Ahmed Hamdan, Ahmed Aljabri and Zeinab Zalat; Formal analysis, Amira Galal, Karema Abu –Elfotuha, Hanan Alshareef, Ahmed Hamdan, Ahmed Aljabri and Mohannad Alshibani; Funding acquisition, Ahmed Alatawi, Hanan Alshareef, Ahmed Hamdan, Ahmed Aljabri and Mohannad Alshibani; Investigation, Nahla Teama and Ahmed Alatawi; Methodology, Amira Galal, Karema Abu –Elfotuha and Ahmed Hamdan; Project administration, Nahla Teama and Zeinab Zalat; Resources, Nahla Teama, Hanan Alshareef and Zeinab Zalat; Software, Amira Galal and Ahmed Aljabri; Supervision, Nahla Teama; Validation, Ahmed Hamdan, Ahmed Aljabri and Zeinab Zalat; Writing – original draft, Amira Galal, Nahla Teama, Karema Abu –Elfotuha, Ahmed Aljabri, Mohannad Alshibani and Zeinab Zalat; Writing – review &amp; editing, Ahmed Alatawi, Hanan Alshareef, Ahmed Hamdan and Mohannad Alshibani.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This research received no external funding.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The datasets used and/ or analyzed during the current study are available from the corresponding author on reasonable request.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par62">Our research conducted on patients, and also the patients’ data, was done in compliance with the Helsinki Declaration (<a href="https://www.wma.net/policies-post/wma-declaration-of-helsinki/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.wma.net/policies-post/wma-declaration-of-helsinki/</a>). Besides, this study’s research was granted authorization by the Research Ethics Committee (REC), Faculty of Medicine, Ain Shams University, No. (FMASU MS UNIV 15/2022) dated to 15/12/2022, and the Ethical Committee in the Faculty of Pharmacy (Girls), Al-Azhar University, No. (313) dated to 22/12/2022. This study was authorized by <a href="https://clinicaltrials.gov/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT05284656" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05284656</a>) and the first date of registration was 16/02/2022.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par63">All patients were assigned to write an informed consent. A written informed consent has been obtained from each patient to publish this paper.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par64">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Floege J. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):S1–69.
</cite> [<a href="https://doi.org/10.1016/j.kint.2023.09.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38182286/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rovin%20BH,%20Ayoub%20IM,%20Chan%20TM,%20Liu%20ZH,%20Mej%C3%ADa-Vilet%20JM,%20Floege%20J.%20KDIGO%202024%20clinical%20practice%20guideline%20for%20the%20management%20of%20LUPUS%20NEPHRITIS.%20Kidney%20Int.%202024;105(1S):S1%E2%80%9369." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Jadoul M, Aoun M, Imani MM. The major global burden of chronic kidney disease. Lancet Glob Health. 2024;12(3):e342–3.
</cite> [<a href="https://doi.org/10.1016/S2214-109X(24)00050-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38365398/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jadoul%20M,%20Aoun%20M,%20Imani%20MM.%20The%20major%20global%20burden%20of%20chronic%20kidney%20disease.%20Lancet%20Glob%20Health.%202024;12(3):e342%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Chesnaye NC, Ortiz A, Zoccali C, Stel VS, Jager KJ. The impact of population ageing on the burden of chronic kidney disease. Nat Rev Nephrol. 2024;20(9):569–85.
</cite> [<a href="https://doi.org/10.1038/s41581-024-00863-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39025992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chesnaye%20NC,%20Ortiz%20A,%20Zoccali%20C,%20Stel%20VS,%20Jager%20KJ.%20The%20impact%20of%20population%20ageing%20on%20the%20burden%20of%20chronic%20kidney%20disease.%20Nat%20Rev%20Nephrol.%202024;20(9):569%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)00519-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34175022/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kalantar-Zadeh%20K,%20Jafar%20TH,%20Nitsch%20D,%20Neuen%20BL,%20Perkovic%20V.%20Chronic%20kidney%20disease.%20Lancet.%202021;398(10302):786%E2%80%93802." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Gusev E, Solomatina L, Zhuravleva Y, Sarapultsev A. The pathogenesis of End-Stage renal disease from the standpoint of the theory of general pathological processes of inflammation. Int J Mol Sci. 2021;22(21):11453.
</cite> [<a href="https://doi.org/10.3390/ijms222111453" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8584056/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34768884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gusev%20E,%20Solomatina%20L,%20Zhuravleva%20Y,%20Sarapultsev%20A.%20The%20pathogenesis%20of%20End-Stage%20renal%20disease%20from%20the%20standpoint%20of%20the%20theory%20of%20general%20pathological%20processes%20of%20inflammation.%20Int%20J%20Mol%20Sci.%202021;22(21):11453." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, Agarwal R, Mark PB, Kotanko P, Ferro CJ, Wanner C, Burnier M, Vanholder R, Wiecek A. Cardiovascular complications in chronic kidney disease: a review from the European renal and cardiovascular medicine working group of the European renal association. Cardiovasc Res. 2023;119(11):2017–32.
</cite> [<a href="https://doi.org/10.1093/cvr/cvad083" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10478756/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37249051/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zoccali%20C,%20Mallamaci%20F,%20Adamczak%20M,%20de%20Oliveira%20RB,%20Massy%20ZA,%20Sarafidis%20P,%20Agarwal%20R,%20Mark%20PB,%20Kotanko%20P,%20Ferro%20CJ,%20Wanner%20C,%20Burnier%20M,%20Vanholder%20R,%20Wiecek%20A.%20Cardiovascular%20complications%20in%20chronic%20kidney%20disease:%20a%20review%20from%20the%20European%20renal%20and%20cardiovascular%20medicine%20working%20group%20of%20the%20European%20renal%20association.%20Cardiovasc%20Res.%202023;119(11):2017%E2%80%9332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Ju A, Teixeira-Pinto A, Tong A, Smith AC, Unruh M, Davison SN, Dapueto J, Dew MA, Fluck R, Germain MJ, Jassal SV, Obrador, G T, O’Donoghue D, Viecelli AK, Strippoli G, Ruospo M, Timofte D, Sharma A, Au E, Howell M, Costa DS, Anumudu S, Craig JC, Rutherford C. Validation of a core Patient-Reported outcome measure for fatigue in patients receiving hemodialysis: the SONG-HD fatigue instrument. Clin J Am Soc Nephrol. 2020;15(11):1614–21.
</cite> [<a href="https://doi.org/10.2215/CJN.05880420" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7646231/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33093215/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ju%20A,%20Teixeira-Pinto%20A,%20Tong%20A,%20Smith%20AC,%20Unruh%20M,%20Davison%20SN,%20Dapueto%20J,%20Dew%20MA,%20Fluck%20R,%20Germain%20MJ,%20Jassal%20SV,%20Obrador,%20G%20T,%20O%E2%80%99Donoghue%20D,%20Viecelli%20AK,%20Strippoli%20G,%20Ruospo%20M,%20Timofte%20D,%20Sharma%20A,%20Au%20E,%20Howell%20M,%20Costa%20DS,%20Anumudu%20S,%20Craig%20JC,%20Rutherford%20C.%20Validation%20of%20a%20core%20Patient-Reported%20outcome%20measure%20for%20fatigue%20in%20patients%20receiving%20hemodialysis:%20the%20SONG-HD%20fatigue%20instrument.%20Clin%20J%20Am%20Soc%20Nephrol.%202020;15(11):1614%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>El-Haggar SM, Hegazy SK, Abd-Elsalam SM, Bahaa MM. Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with Mebeverine. Biomed Pharmacother. 2022;145:112399.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2021.112399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34775240/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?El-Haggar%20SM,%20Hegazy%20SK,%20Abd-Elsalam%20SM,%20Bahaa%20MM.%20Pentoxifylline,%20a%20nonselective%20phosphodiesterase%20inhibitor,%20in%20adjunctive%20therapy%20in%20patients%20with%20irritable%20bowel%20syndrome%20treated%20with%20Mebeverine.%20Biomed%20Pharmacother.%202022;145:112399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Bahaa MM, Hegazy SK, Maher MM, Bahgat MM, El-Haggar SM. Pentoxifylline in patients with ulcerative colitis treated with Mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study. Inflammopharmacology. 2024;32(5):3247–58.
</cite> [<a href="https://doi.org/10.1007/s10787-024-01560-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39192162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bahaa%20MM,%20Hegazy%20SK,%20Maher%20MM,%20Bahgat%20MM,%20El-Haggar%20SM.%20Pentoxifylline%20in%20patients%20with%20ulcerative%20colitis%20treated%20with%20Mesalamine%20by%20modulation%20of%20IL-6/STAT3,%20ZO-1,%20and%20S1P%20pathways:%20a%20randomized%20controlled%20double-blinded%20study.%20Inflammopharmacology.%202024;32(5):3247%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2020;10(10):CD005262.
</cite> [<a href="https://doi.org/10.1002/14651858.CD005262.pub4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8094235/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33063850/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Broderick%20C,%20Forster%20R,%20Abdel-Hadi%20M,%20Salhiyyah%20K.%20Pentoxifylline%20for%20intermittent%20claudication.%20Cochrane%20Database%20Syst%20Rev.%202020;10(10):CD005262." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab J. 2022;46(2):181–97.
</cite> [<a href="https://doi.org/10.4093/dmj.2021.0329" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8987689/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35385633/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jung%20CY,%20Yoo%20TH.%20Pathophysiologic%20mechanisms%20and%20potential%20biomarkers%20in%20diabetic%20kidney%20disease.%20Diabetes%20Metab%20J.%202022;46(2):181%E2%80%9397." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, Tagua VG, Hernández-Carballo C, Ferri C, Rodríguez-Rodríguez AE, Mora-Fernández C, Navarro-González JF. Inflammatory targets in diabetic nephropathy. J Clin Med. 2020;9(2):458.
</cite> [<a href="https://doi.org/10.3390/jcm9020458" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7074396/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32046074/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Donate-Correa%20J,%20Luis-Rodr%C3%ADguez%20D,%20Mart%C3%ADn-N%C3%BA%C3%B1ez%20E,%20Tagua%20VG,%20Hern%C3%A1ndez-Carballo%20C,%20Ferri%20C,%20Rodr%C3%ADguez-Rodr%C3%ADguez%20AE,%20Mora-Fern%C3%A1ndez%20C,%20Navarro-Gonz%C3%A1lez%20JF.%20Inflammatory%20targets%20in%20diabetic%20nephropathy.%20J%20Clin%20Med.%202020;9(2):458." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, Jeandet P, Saad HM, Batiha GE. A Raising dawn of Pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology. 2022;30(3):799–809.
</cite> [<a href="https://doi.org/10.1007/s10787-022-00993-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9051499/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35486310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mostafa-Hedeab%20G,%20Al-Kuraishy%20HM,%20Al-Gareeb%20AI,%20Jeandet%20P,%20Saad%20HM,%20Batiha%20GE.%20A%20Raising%20dawn%20of%20Pentoxifylline%20in%20management%20of%20inflammatory%20disorders%20in%20Covid-19.%20Inflammopharmacology.%202022;30(3):799%E2%80%93809." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Ly L, Chan D, Aarabi M, Landry M, Behan NA, MacFarlane AJ, Trasler J. Intergenerational impact of paternal lifetime exposures to both folic acid deficiency and supplementation on reproductive outcomes and imprinted gene methylation. Mol Hum Reprod. 2017;23(7):461–77.
</cite> [<a href="https://doi.org/10.1093/molehr/gax029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5909862/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28535307/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ly%20L,%20Chan%20D,%20Aarabi%20M,%20Landry%20M,%20Behan%20NA,%20MacFarlane%20AJ,%20Trasler%20J.%20Intergenerational%20impact%20of%20paternal%20lifetime%20exposures%20to%20both%20folic%20acid%20deficiency%20and%20supplementation%20on%20reproductive%20outcomes%20and%20imprinted%20gene%20methylation.%20Mol%20Hum%20Reprod.%202017;23(7):461%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Chan CW, Lin BF. Folate deficiency enhanced inflammation and exacerbated renal fibrosis in High-Fat High-Fructose Diet-Fed mice. Nutrients. 2023;15(16):3616.
</cite> [<a href="https://doi.org/10.3390/nu15163616" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10458828/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37630806/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chan%20CW,%20Lin%20BF.%20Folate%20deficiency%20enhanced%20inflammation%20and%20exacerbated%20renal%20fibrosis%20in%20High-Fat%20High-Fructose%20Diet-Fed%20mice.%20Nutrients.%202023;15(16):3616." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>C Liew S. Folic acid and diseases - supplement it or not? Rev Assoc Med Bras (1992). 2016;62(1):90–100.
</cite> [<a href="https://doi.org/10.1590/1806-9282.62.01.90" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27008500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?C%20Liew%20S.%20Folic%20acid%20and%20diseases%20-%20supplement%20it%20or%20not?%20Rev%20Assoc%20Med%20Bras%20(1992).%202016;62(1):90%E2%80%93100." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Cianciolo G, De Pascalis A, Di Lullo L, Ronco C, Zannini C, La Manna G. Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: which comes first. ? Cardiorenal Med. 2017;7(4):255–66.
</cite> [<a href="https://doi.org/10.1159/000471813" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5662962/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29118764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cianciolo%20G,%20De%20Pascalis%20A,%20Di%20Lullo%20L,%20Ronco%20C,%20Zannini%20C,%20La%20Manna%20G.%20Folic%20acid%20and%20homocysteine%20in%20chronic%20kidney%20disease%20and%20cardiovascular%20disease%20progression:%20which%20comes%20first.%20?%20Cardiorenal%20Med.%202017;7(4):255%E2%80%9366." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Chen W, Feng J, Ji P, Liu Y, Wan H, Zhang J. Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis. BMC Nephrol. 2023;24(1):247.
</cite> [<a href="https://doi.org/10.1186/s12882-023-03295-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10463317/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37612681/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20W,%20Feng%20J,%20Ji%20P,%20Liu%20Y,%20Wan%20H,%20Zhang%20J.%20Association%20of%20hyperhomocysteinemia%20and%20chronic%20kidney%20disease%20in%20the%20general%20population:%20a%20systematic%20review%20and%20meta-analysis.%20BMC%20Nephrol.%202023;24(1):247." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015,14,6.</cite> [<a href="https://doi.org/10.1186/1475-2891-14-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4326479/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25577237/" class="usa-link">PubMed</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Paganelli F, Mottola G, Fromonot J, Marlinge M, Deharo P, Guieu R, Ruf J. Hyperhomocysteinemia and cardiovascular disease: is the adenosinergic system the missing link?? Int J Mol Sci. 2021;22(4):1690.
</cite> [<a href="https://doi.org/10.3390/ijms22041690" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7914561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33567540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Paganelli%20F,%20Mottola%20G,%20Fromonot%20J,%20Marlinge%20M,%20Deharo%20P,%20Guieu%20R,%20Ruf%20J.%20Hyperhomocysteinemia%20and%20cardiovascular%20disease:%20is%20the%20adenosinergic%20system%20the%20missing%20link??%20Int%20J%20Mol%20Sci.%202021;22(4):1690." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet. 2000;355(9212):1345–50.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(00)02124-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10776760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Volmink%20J,%20Matchaba%20P,%20Garner%20P.%20Directly%20observed%20therapy%20and%20treatment%20adherence.%20Lancet.%202000;355(9212):1345%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Oedingen C, van Gestel R, Huls SP, Granic G, de Bekker-Grob EW, Veldwijk J. Association of medication adherence with treatment preferences: incentivizing truthful self-reporting. Eur J Health Econ. 2025;22:1–4.</cite> [<a href="https://doi.org/10.1007/s10198-025-01760-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40075020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oedingen%20C,%20van%20Gestel%20R,%20Huls%20SP,%20Granic%20G,%20de%20Bekker-Grob%20EW,%20Veldwijk%20J.%20Association%20of%20medication%20adherence%20with%20treatment%20preferences:%20incentivizing%20truthful%20self-reporting.%20Eur%20J%20Health%20Econ.%202025;22:1%E2%80%934." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>De Vries J, Michielsen HJ, Van Heck GL. Assessment of fatigue among working people: a comparison of six questionnaires. Occup Environ Med. 2003;60(Suppl 1):i10–5.
</cite> [<a href="https://doi.org/10.1136/oem.60.suppl_1.i10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1765720/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12782741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Vries%20J,%20Michielsen%20HJ,%20Van%20Heck%20GL.%20Assessment%20of%20fatigue%20among%20working%20people:%20a%20comparison%20of%20six%20questionnaires.%20Occup%20Environ%20Med.%202003;60(Suppl%201):i10%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov. 2008;7(11):936–53.
</cite> [<a href="https://doi.org/10.1038/nrd2685" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18846102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Perico%20N,%20Benigni%20A,%20Remuzzi%20G.%20Present%20and%20future%20drug%20treatments%20for%20chronic%20kidney%20diseases:%20evolving%20targets%20in%20renoprotection.%20Nat%20Rev%20Drug%20Discov.%202008;7(11):936%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 2006;69(8):1410–5.
</cite> [<a href="https://doi.org/10.1038/sj.ki.5000302" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16541021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20YM,%20Lin%20SL,%20Chiang%20WC,%20Wu%20KD,%20Tsai%20TJ.%20Pentoxifylline%20ameliorates%20proteinuria%20through%20suppression%20of%20renal%20monocyte%20chemoattractant%20protein-1%20in%20patients%20with%20proteinuric%20primary%20glomerular%20diseases.%20Kidney%20Int.%202006;69(8):1410%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B. Effect of Pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochim Pol. 2010;57(1):119–23.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/20309434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Renke%20M,%20Tylicki%20L,%20Rutkowski%20P,%20Knap%20N,%20Zietkiewicz%20M,%20Neuwelt%20A,%20Aleksandrowicz%20E,%20%C5%81ysiak-Szyd%C5%82owska%20W,%20Wo%C5%BAniak%20M,%20Rutkowski%20B.%20Effect%20of%20Pentoxifylline%20on%20proteinuria,%20markers%20of%20tubular%20injury%20and%20oxidative%20stress%20in%20non-diabetic%20patients%20with%20chronic%20kidney%20disease%20-%20placebo%20controlled,%20randomized,%20cross-over%20study.%20Acta%20Biochim%20Pol.%202010;57(1):119%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of Pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53(4):606–16.
</cite> [<a href="https://doi.org/10.1053/j.ajkd.2008.11.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19216016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Perkins%20RM,%20Aboudara%20MC,%20Uy%20AL,%20Olson%20SW,%20Cushner%20HM,%20Yuan%20CM.%20Effect%20of%20Pentoxifylline%20on%20GFR%20decline%20in%20CKD:%20a%20pilot,%20double-blind,%20randomized,%20placebo-controlled%20trial.%20Am%20J%20Kidney%20Dis.%202009;53(4):606%E2%80%9316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Adam WR, Wright JR. Use of Renin angiotensin system inhibitors in patients with chronic kidney disease. Intern Med J. 2016;46(5):626–30.
</cite> [<a href="https://doi.org/10.1111/imj.13060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27170242/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Adam%20WR,%20Wright%20JR.%20Use%20of%20Renin%20angiotensin%20system%20inhibitors%20in%20patients%20with%20chronic%20kidney%20disease.%20Intern%20Med%20J.%202016;46(5):626%E2%80%9330." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, Fernández-Juárez G, de Sequera P, Verdalles U, Delgado R, Torres A, Arroyo D, Abad S, Ortiz A, Luño J. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255–63.
</cite> [<a href="https://doi.org/10.1007/s10557-018-6802-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29943364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Goicoechea%20M,%20de%20Vinuesa%20SG,%20Quiroga%20B,%20Verde%20E,%20Bernis%20C,%20Morales%20E,%20Fern%C3%A1ndez-Ju%C3%A1rez%20G,%20de%20Sequera%20P,%20Verdalles%20U,%20Delgado%20R,%20Torres%20A,%20Arroyo%20D,%20Abad%20S,%20Ortiz%20A,%20Lu%C3%B1o%20J.%20Aspirin%20for%20primary%20prevention%20of%20cardiovascular%20disease%20and%20renal%20disease%20progression%20in%20chronic%20kidney%20disease%20patients:%20a%20multicenter%20randomized%20clinical%20trial%20(AASER%20Study).%20Cardiovasc%20Drugs%20Ther.%202018;32(3):255%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM. HERO study collaborative group. A randomized, placebo-controlled trial of Pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the handling erythropoietin resistance with oxpentifylline (HERO) trial. Am J Kidney Dis. 2015;65(1):49–57.
</cite> [<a href="https://doi.org/10.1053/j.ajkd.2014.06.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25115616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Johnson%20DW,%20Pascoe%20EM,%20Badve%20SV,%20Dalziel%20K,%20Cass%20A,%20Clarke%20P,%20Ferrari%20P,%20McDonald%20SP,%20Morrish%20AT,%20Pedagogos%20E,%20Perkovic%20V,%20Reidlinger%20D,%20Scaria%20A,%20Walker%20R,%20Vergara%20LA,%20Hawley%20CM.%20HERO%20study%20collaborative%20group.%20A%20randomized,%20placebo-controlled%20trial%20of%20Pentoxifylline%20on%20erythropoiesis-stimulating%20agent%20hyporesponsiveness%20in%20anemic%20patients%20with%20CKD:%20the%20handling%20erythropoietin%20resistance%20with%20oxpentifylline%20(HERO)%20trial.%20Am%20J%20Kidney%20Dis.%202015;65(1):49%E2%80%9357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Nanayakkara PW, van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, Teerlink T, van Dorp W, Stehouwer CD. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine Lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant therapy in chronic renal insufficiency (ATIC) study. Arch Intern Med. 2007;167(12):1262–70.
</cite> [<a href="https://doi.org/10.1001/archinte.167.12.1262" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17592099/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nanayakkara%20PW,%20van%20Guldener%20C,%20ter%20Wee%20PM,%20Scheffer%20PG,%20van%20Ittersum%20FJ,%20Twisk%20JW,%20Teerlink%20T,%20van%20Dorp%20W,%20Stehouwer%20CD.%20Effect%20of%20a%20treatment%20strategy%20consisting%20of%20pravastatin,%20vitamin%20E,%20and%20homocysteine%20Lowering%20on%20carotid%20intima-media%20thickness,%20endothelial%20function,%20and%20renal%20function%20in%20patients%20with%20mild%20to%20moderate%20chronic%20kidney%20disease:%20results%20from%20the%20Anti-Oxidant%20therapy%20in%20chronic%20renal%20insufficiency%20(ATIC)%20study.%20Arch%20Intern%20Med.%202007;167(12):1262%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019;34(6):975–91.
</cite> [<a href="https://doi.org/10.1007/s00467-018-4005-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30105414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Daenen%20K,%20Andries%20A,%20Mekahli%20D,%20Van%20Schepdael%20A,%20Jouret%20F,%20Bammens%20B.%20Oxidative%20stress%20in%20chronic%20kidney%20disease.%20Pediatr%20Nephrol.%202019;34(6):975%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW. On behalf of the hero study collaborative group. the effect of Pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hypo responsiveness: Sub-study of the HERO trial. Redox Rep. 2016;21(1):14–23.
</cite> [<a href="https://doi.org/10.1179/1351000215Y.0000000022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6837737/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26083328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20L,%20Coombes%20J,%20Pascoe%20EM,%20Badve%20SV,%20Dalziel%20K,%20Cass%20A,%20Clarke%20P,%20Ferrari%20P,%20McDonald%20SP,%20Morrish%20AT,%20Pedagogos%20E,%20Perkovic%20V,%20Reidlinger%20D,%20Scaria%20A,%20Walker%20R,%20Vergara%20LA,%20Hawley%20CM,%20Johnson%20DW.%20On%20behalf%20of%20the%20hero%20study%20collaborative%20group.%20the%20effect%20of%20Pentoxifylline%20on%20oxidative%20stress%20in%20chronic%20kidney%20disease%20patients%20with%20erythropoiesis-stimulating%20agent%20hypo%20responsiveness:%20Sub-study%20of%20the%20HERO%20trial.%20Redox%20Rep.%202016;21(1):14%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010;303(16):1603–9.
</cite> [<a href="https://doi.org/10.1001/jama.2010.490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20424250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?House%20AA,%20Eliasziw%20M,%20Cattran%20DC,%20Churchill%20DN,%20Oliver%20MJ,%20Fine%20A,%20Dresser%20GK,%20Spence%20JD.%20Effect%20of%20B-vitamin%20therapy%20on%20progression%20of%20diabetic%20nephropathy:%20a%20randomized%20controlled%20trial.%20JAMA.%202010;303(16):1603%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Yang H, Juang SY, Liao KF, Chen YH. Comparing the effect of folic acid and Pentoxifylline on delaying Dialysis initiation in patients with advanced chronic kidney disease. Nutrients. 2019;11(9):2192.
</cite> [<a href="https://doi.org/10.3390/nu11092192" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6769878/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31547288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20H,%20Juang%20SY,%20Liao%20KF,%20Chen%20YH.%20Comparing%20the%20effect%20of%20folic%20acid%20and%20Pentoxifylline%20on%20delaying%20Dialysis%20initiation%20in%20patients%20with%20advanced%20chronic%20kidney%20disease.%20Nutrients.%202019;11(9):2192." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Zakaria H, Hamdy NA, Sayed-Ahmed NA, El-Mallah A. Pentoxifylline improves anemia through its novel effect on hypoxia-inducible factor-2 alpha in Hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial. Postgrad Med. 2024;136(8):847–54.
</cite> [<a href="https://doi.org/10.1080/00325481.2024.2426448" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39499142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zakaria%20H,%20Hamdy%20NA,%20Sayed-Ahmed%20NA,%20El-Mallah%20A.%20Pentoxifylline%20improves%20anemia%20through%20its%20novel%20effect%20on%20hypoxia-inducible%20factor-2%20alpha%20in%20Hemodialysis%20patients:%20a%20randomized,%20double-blind,%20placebo-controlled%20clinical%20trial.%20Postgrad%20Med.%202024;136(8):847%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fernández C, Navarro-González JF. Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizons. J Clin Med. 2019;8(3):287.
</cite> [<a href="https://doi.org/10.3390/jcm8030287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6463074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30818852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Donate-Correa%20J,%20Tagua%20VG,%20Ferri%20C,%20Mart%C3%ADn-N%C3%BA%C3%B1ez%20E,%20Hern%C3%A1ndez-Carballo%20C,%20Ure%C3%B1a-Torres%20P,%20Ruiz-Ortega%20M,%20Ortiz%20A,%20Mora-Fern%C3%A1ndez%20C,%20Navarro-Gonz%C3%A1lez%20JF.%20Pentoxifylline%20for%20renal%20protection%20in%20diabetic%20kidney%20disease.%20A%20model%20of%20old%20drugs%20for%20new%20horizons.%20J%20Clin%20Med.%202019;8(3):287." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Skoie I, Dalen I, Ternowitz T, Jonsson G, Kvivik I, Norheim K. Omdal R. Fatigue in psoriasis: a controlled study. Br J Dermatol. 2017;177(2):505–12.
</cite> [<a href="https://doi.org/10.1111/bjd.15375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28182255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Skoie%20I,%20Dalen%20I,%20Ternowitz%20T,%20Jonsson%20G,%20Kvivik%20I,%20Norheim%20K.%20Omdal%20R.%20Fatigue%20in%20psoriasis:%20a%20controlled%20study.%20Br%20J%20Dermatol.%202017;177(2):505%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Machado MO, Kang NC, Tai F, Sambhi RDS, Berk M, Carvalho AF, Chada LP, Merola JF, Piguet V, Alavi A. Measuring fatigue: a meta-review. Int J Dermatol. 2021;60(9):1053–69.
</cite> [<a href="https://doi.org/10.1111/ijd.15341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33301180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Machado%20MO,%20Kang%20NC,%20Tai%20F,%20Sambhi%20RDS,%20Berk%20M,%20Carvalho%20AF,%20Chada%20LP,%20Merola%20JF,%20Piguet%20V,%20Alavi%20A.%20Measuring%20fatigue:%20a%20meta-review.%20Int%20J%20Dermatol.%202021;60(9):1053%E2%80%9369." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Zyga S, Alikari V, Sachlas A, Fradelos EC, Stathoulis J, Panoutsopoulos G, Georgopoulou M, Theophilou P, Lavdaniti M. Assessment of fatigue in end stage renal disease patients undergoing hemodialysis: prevalence and associated factors. Med Arch. 2015;69(6):376–80.
</cite> [<a href="https://doi.org/10.5455/medarh.2015.69.376-380" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4720468/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26843728/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zyga%20S,%20Alikari%20V,%20Sachlas%20A,%20Fradelos%20EC,%20Stathoulis%20J,%20Panoutsopoulos%20G,%20Georgopoulou%20M,%20Theophilou%20P,%20Lavdaniti%20M.%20Assessment%20of%20fatigue%20in%20end%20stage%20renal%20disease%20patients%20undergoing%20hemodialysis:%20prevalence%20and%20associated%20factors.%20Med%20Arch.%202015;69(6):376%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care. 2018;41(8):1817–20. 10.2337/dc18-0078. Epub 2018 Jun 4. PMID: 29866645.</cite> [<a href="https://doi.org/10.2337/dc18-0078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29866645/" class="usa-link">PubMed</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Moosaie F, Rabizadeh S, Fallahzadeh A, Sheikhy A, Meysamie A, Dehghani Firouzabadi F, Nakhjavani M, Esteghamati A. Effects of pentoxifylline on serum markers of diabetic nephropathy in type 2 diabetes. Diabetes Ther. 2022;13(5):1023–36. 10.1007/s13300-022-01250-y. Epub 2022 Apr 5. PMID: 35380410; PMCID: PMC9076784.
</cite> [<a href="https://doi.org/10.1007/s13300-022-01250-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9076784/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35380410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moosaie%20F,%20Rabizadeh%20S,%20Fallahzadeh%20A,%20Sheikhy%20A,%20Meysamie%20A,%20Dehghani%20Firouzabadi%20F,%20Nakhjavani%20M,%20Esteghamati%20A.%20Effects%20of%20pentoxifylline%20on%20serum%20markers%20of%20diabetic%20nephropathy%20in%20type%202%20diabetes.%20Diabetes%20Ther.%202022;13(5):1023%E2%80%9336.%2010.1007/s13300-022-01250-y.%20Epub%202022%20Apr%205.%20PMID:%2035380410;%20PMCID:%20PMC9076784." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Ghorbani A, Omidvar B, Beladi-Mousavi SS, Lak E, Vaziri S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia. 2012;32(6):790-6. 10.3265/Nefrologia.pre2012.Jun.11242. PMID: 23169362.</cite> [<a href="https://doi.org/10.3265/Nefrologia.pre2012.Jun.11242" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23169362/" class="usa-link">PubMed</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, Ferrari P, MacDonald S, Pedagogos E, Cass A. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol. 2008;9:8.
</cite> [<a href="https://doi.org/10.1186/1471-2369-9-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2519060/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18671885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Johnson%20DW,%20Hawley%20CM,%20Rosser%20B,%20Beller%20E,%20Thompson%20C,%20Fassett%20RG,%20Ferrari%20P,%20MacDonald%20S,%20Pedagogos%20E,%20Cass%20A.%20Oxpentifylline%20versus%20placebo%20in%20the%20treatment%20of%20erythropoietin-resistant%20anaemia:%20a%20randomized%20controlled%20trial.%20BMC%20Nephrol.%202008;9:8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15(7):1877–82.
</cite> [<a href="https://doi.org/10.1097/01.asn.0000131523.17045.56" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15213276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cooper%20A,%20Mikhail%20A,%20Lethbridge%20MW,%20Kemeny%20DM,%20Macdougall%20IC.%20Pentoxifylline%20improves%20hemoglobin%20levels%20in%20patients%20with%20erythropoietin-resistant%20anemia%20in%20renal%20failure.%20J%20Am%20Soc%20Nephrol.%202004;15(7):1877%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Fukuda S, Koyama H, Kondo K, Fujii H, Hirayama Y, Tabata T, Okamura M, Yamakawa T, Okada S, Hirata S, Kiyama H, Kajimoto O, Watanabe Y, Inaba M, Nishizawa Y. Effects of nutritional supplementation on fatigue, and autonomic and immune dysfunction in patients with end-stage renal disease: a randomized, double-blind, placebo-controlled, multicentre trial. PLoS ONE. 2015;10(3):e0119578.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0119578" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4352065/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25746727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fukuda%20S,%20Koyama%20H,%20Kondo%20K,%20Fujii%20H,%20Hirayama%20Y,%20Tabata%20T,%20Okamura%20M,%20Yamakawa%20T,%20Okada%20S,%20Hirata%20S,%20Kiyama%20H,%20Kajimoto%20O,%20Watanabe%20Y,%20Inaba%20M,%20Nishizawa%20Y.%20Effects%20of%20nutritional%20supplementation%20on%20fatigue,%20and%20autonomic%20and%20immune%20dysfunction%20in%20patients%20with%20end-stage%20renal%20disease:%20a%20randomized,%20double-blind,%20placebo-controlled,%20multicentre%20trial.%20PLoS%20ONE.%202015;10(3):e0119578." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12363063/bin/12882_2025_4399_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (19.1KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12363063/bin/12882_2025_4399_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (32.4KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The datasets used and/ or analyzed during the current study are available from the corresponding author on reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from BMC Nephrology are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12882-025-04399-3"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12882_2025_Article_4399.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (3.2 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12363063/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12363063/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12363063%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363063/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12363063/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12363063/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40826392/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12363063/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40826392/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12363063/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12363063/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="Ze6jP5emePrs8Zh7jyYOxkCYbrrIchTQXJlmrZgzxsAY2kXMrnM1DbphvJaeBcTO">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
